Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022.

Détails

Ressource 1Télécharger: 35929427_BIB_6DDFE21CA95A.pdf (290.83 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_6DDFE21CA95A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022.
Périodique
Euro surveillance
Auteur⸱e⸱s
Amati R., Frei A., Kaufmann M., Sabatini S., Pellaton C., Fehr J., Albanese E., Puhan M.A.
Collaborateur⸱rice⸱s
Corona Immunitas Research Group
Contributeur⸱rice⸱s
Bochud Murielle , Bodenmann Patrick , Butty Audrey , D'Acremont Valérie , Duperrex Olivier , Dupraz Julien , Egger  Malik , Estoppey  Sandrine , Faivre  Vincent , Felappi  Andrea , Fenwick Craig , Gonseth Nusslé Semira , Jendly  Emilie , Pantaleo Giuseppe , Pasquier Jérôme , Pellaton Céline , Sanchis Zozaya Javier , Schlüter Virginie , Steiner-Dubuis  Amélie , Thabard  Julien , Vassaux  Sophie , Zuppinger  Claire
ISSN
1560-7917 (Electronic)
ISSN-L
1025-496X
Statut éditorial
Publié
Date de publication
08/2022
Peer-reviewed
Oui
Volume
27
Numéro
31
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Functional immunity (defined here as serum neutralising capacity) critically contributes to conferring protection against SARS-CoV-2 infection and severe COVID-19. This cross-sectional analysis of a prospective, population-based cohort study included 1,894 randomly-selected 16 to 99-year-old participants from two Swiss cantons in March 2022. Of these, 97.6% (95% CI: 96.8-98.2%) had anti-spike IgG antibodies, and neutralising capacity was respectively observed for 94%, 92% and 88% against wild-type SARS-CoV-2, Delta and Omicron variants. Studying functional immunity to inform and monitor vaccination campaigns is crucial.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Neutralizing, Antibodies, Viral, COVID-19/immunology, COVID-19/prevention & control, COVID-19 Vaccines/administration & dosage, Cross-Sectional Studies, Humans, Immunization Programs, Immunization, Secondary, Middle Aged, Prospective Studies, SARS-CoV-2, Spike Glycoprotein, Coronavirus/immunology, Switzerland/epidemiology, Young Adult, neutralising activity, seroprevalence, variants of concern
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/08/2022 9:41
Dernière modification de la notice
23/01/2024 8:27
Données d'usage